Clinical Trial Update: Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment [Phase 1, Phase 2]

View source ↗

Summary

Completed Phase 1/2 trial evaluating the combination of rigosertib and nivolumab in KRAS-positive non-small cell lung cancer patients who progressed after first…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Lung
• Non-small Cell Lung Cancer

Drugs mentioned

• Rigosertib (rigosertib)
• nivolumab (nivolumab)

Snippet

Sponsor: Icahn School of Medicine at Mount Sinai | Conditions: Non-small Cell Lung Cancer, Adenocarcinoma | Phase 1, Phase 2 | Status: COMPLETED